EUROAPI, Priothera Enter CDMO Collaboration

Partner to develop and industrialize the manufacturing process of mocravimod, an innovative oncology molecule.

Author Image

By: Charlie Sternberg

Associate Editor

EUROAPI has implemented a 5-year development and manufacturing agreement with Priothera, a biotechnology company specializing in molecules for the treatment of hematological malignancies and for the improvement of CAR-T cell therapies.   As part of this collaboration, EUROAPI will develop and industrialize the manufacturing process of mocravimod, an innovative oncology molecule, through its Contract Development and Manufacturing Organization (CDMO) activity. This project will be carried out at...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters